Patent ID: 8828971

Claim:
A method comprising: a. obtaining a composition for parenteral or enteral administration comprising a galacto-rhamnogalacturonate in a pharmaceutical acceptable carrier, and b. administering to a subject in need thereof an effective dose of the composition that results in at least one of the following: at least a 10% reduction in proteinuria or at least a 10% reduction in the rate of increase of proteinuria; at least a 10% increase in glomerular filtration rate or at least a 10% reduction in the rate of decline of glomerular filtration rate; at least a 10% reduction of mesangial extracellular matrix or at least a 10% reduction in the rate of increase of mesangial extracellular matrix; at least a 5% reduction in the glomerular capillary basement membrane thickness; at least a 10% reduction in the fractional volume of the mesangium or at least a 10% reduction in the rate of increase of the fractional volume of the mesangium; at least a 10% reduction in the interstitial tubular volume or at least a 10% reduction in the rate of increase in the interstitial tubular volume; at least a 10% reduction in the amount of collagen in the interstitial tubular space or at least a 10% reduction in the rate of increase of the collagen in the interstitial tubular space; at least 10% change in the level of the serum biomarkers of diabetic nephropathy; wherein the subject in need thereof has at least one of the following: a primary glomerulopathic disease, a secondary glomerulopathic disease, and renal tubule-interstitial disorder, and wherein the effective dose is equivalent to an animal dose of 0.1 mg/kg to 9.99 mg/kg.